AVBP
ArriVent BioPharma, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$31.11
+0.25%Next report
Analyst consensus
- Next report date
- Nov 16, 2026
- EPS estimate
- -$1.07
- Revenue estimate
- $800.0K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$1.05
- EPS estimate
- -$0.99
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +3.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $44
- PT range
- $40 – $47
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 16, 2026